Method for assembling bacteriophage gene engineering antibody library gene

Abstract

The invention relates to a gene assembly method of phage genetically engineered antibody library, belonging to the field of biomedical study and clinical applications. The method aims to overcome the problems of the prior art, including poor stability, low efficiency, high mutation probability and low fidelity, and indirect application to humanized single chain antibody study. The technical proposal adopted by the invention comprises the following steps of: obtaining heavy chain variable region gene and light chain variable region gene of a humanized antibody by RT-PCR, and ligating the antibody heavy chain variable region, a linker and the antibody light chain variable region with the pre-designed restriction enzyme cutting sites on two ends of primers using PCR and restriction enzyme method at the same time.

Description

Technical field:

[0001] The invention relates to the field of biomedical research and clinical application, in particular to a method for gene assembly of a phage genetic engineering antibody library. Background technique:

[0002] In recent years, genetic engineering technology has developed rapidly, and a series of genetic engineering drugs have been widely used in clinical practice, and their application scope mainly focuses on genetic engineering drugs and monoclonal antibodies for tumors and AIDS. At present, there are more than 2,200 biotechnology drugs under development worldwide, of which more than 1,700 have entered the clinical trial stage. There are more than 300 biologic drugs in late-stage clinical trials in the United States. In 2001, FDA approved 8 kinds of biotechnology drugs and vaccines and 3 new indications of drugs; in 2002, FDA approved a total of 20 new biotechnology drugs and 15 new indications of biotechnology drugs. In 2003, FDA approved 35 new dru...